NEW YORK (GenomeWeb News) – Accelr8 said today that it has begun a private sale of equity to qualified investors. The company first announced the equity offer following its annual shareholders' meeting on Dec. 16.

Accler8 also provided updates on several recent corporate events, including that of a "going concern" statement by its auditors attributed to recurring losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.